Tempest Therapeutics Inc TPST.OQ TPST.O is expected to show no change in quarterly revenue when it reports results on August 6 (estimated) for the period ending June 30 2025
LSEG's mean analyst estimate for Tempest Therapeutics Inc is for a loss of $2.60 per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Tempest Therapeutics Inc is $9.00, about 16.8% above its last closing price of $7.49
This summary was machine generated August 4 at 20:37 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)